Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10946289 | 0.89 | MAPT (0.62) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL6170431 | 0.88 | KMT2A (0.60) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL11446616 | 0.88 | MAPT (0.58) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL10946509 | 0.86 | ESR1 (0.61) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL1827529 | 0.85 | LMNA (0.56) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL1981486 | 0.85 | KMT2A (0.67) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL10946588 | 0.85 | MAPT (0.60) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL10957478 | 0.85 | MAPT (0.60) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1552568 | 0.84 | LMNA (0.55) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL12933644 | 0.84 | LMNA (0.55) | MAPTKMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2024-05-16 | — | — | US | disclosed |
| EP-3972964-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-30 | — | — | EP | disclosed |
| CN-113874380-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-12-31 | — | — | CN | disclosed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| EP-3037418-B1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| CN-105636956-B | Indole compounds as inhibitors of cellular necrosis | 株式会社LG化学 | 2019-07-09 | — | — | CN | disclosed |
| CN-105985276-B | A kind of 3,4- dibenzamide yl-benzamide derivatives and its preparation method and application | 南京中瑞药业有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-5210092-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0480204-A1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0196910-B1 | Benzo[a]phenazine derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-01-02 | — | — | EP | disclosed |
| US-4686292-A | Benzo[α]phenazine antitumor agents | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1987-08-11 | — | — | US | disclosed |
| EP-0196910-A2 | Benzo[a]phenazine derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4555568-A | Monoazo compounds derived from 3-nitro-4-amino-benzoates and 5-(2'-hydroxy-3'-naphthoylamino)-benzimidazolones | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-11-26 | — | — | US | disclosed |
| US-4379819-A | OIL SOLUBLE MONOAZO DYE | CIBA-GEIGY AG (CH) | 1983-04-12 | — | — | US | disclosed |
| EP-0065811-A1 | Disperse azopyrimidine dyestuffs | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
| US-4094636-A | DIAZOTIZATION | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-13 | — | — | US | disclosed |
| US-4013631-A | SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | MAVS, ZC3HAV1, RNASEH1 | MAPT 3791/4885KMT2A 3174/4885ALDH1A1 1533/4885 |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | MAPT 2077/4885KMT2A 4108/4885ALDH1A1 3181/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | MAPT 1893/4885KMT2A 3771/4885ALDH1A1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.